ATRIUM THERAPEUTICS INCRNA
ASignal's systematic analysis rates RNA as Neutral.
Reflects the latest available analysis · analyzed Oct 13, 2026
The case on RNA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $263.90M total cash and low debt ($1.68M)
- Debt-to-equity ratio of 0.01x indicates minimal leverage risk
- High liquidity with current ratio of 8.73x and quick ratio of 8.38x
- Price near Bollinger Lower Band (7.35) suggesting potential mean reversion
- RSI at 37.28 indicates near-oversold condition, potential for rebound
- Negative price momentum (-0.064) and trading below both SMA20 and SMA50
- MACD below signal line with negative histogram, indicating bearish trend continuation
- Severe negative operating margin (-752.93%) and gross margin (-56.37%)
- Negative revenue growth year-over-year (-21.90%)
- Negative enterprise value ($-121.78M) and negative profit margin (-184.15%)
- No Reddit mentions, suggesting lack of retail investor interest or sentiment catalyst
See the full verdict on RNA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RNA
Most investors never get a second opinion, let alone several. ASignal runs RNA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.